journal
Journals Biotechnology Healthcare

Biotechnology Healthcare

https://read.qxmd.com/read/23267286/new-fdasia-legislation-will-help-biotechs
#1
JOURNAL ARTICLE
New FDASIA Legislation Will Help Biotechs.
Susan Worley
The need to invest in the regulatory environment to support biotechnology innovation is urgent, says Jim Greenwood, president and CEO, Biotechnology Industry Organization.
23267286
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267285/a-truer-way-to-measure-value-of-diagnostic-tests
#2
JOURNAL ARTICLE
A truer way to measure value of diagnostic tests.
Bob Carlson
Helping payers track advanced diagnostics is a must in a health reform environment.
23267285
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267284/as-rems-requirements-simplify-participants-need-to-catch-up
#3
JOURNAL ARTICLE
As REMS Requirements Simplify, Participants Need To Catch Up.
John Carroll
No abstract text is available yet for this article.
23267284
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267283/antibody-drug-conjugates-where-the-action-is-adcs-the-new-frontier
#4
JOURNAL ARTICLE
Antibody-Drug Conjugates: Where the Action Is: ADCs - The New Frontier.
Bob Carlson
Next generation antibody-drug conjugates, like T-DM1, are meant to kill the cancer - not the patient.
23267283
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267282/ms-treatment-is-on-the-cusp-of-something-big-on-the-cusp-of-something-big
#5
JOURNAL ARTICLE
MS Treatment Is on the Cusp of Something Big: On the Cusp of Something Big?
Susan Worley
For so long, multiple sclerosis has frustrated physicians and patients. With bold new treatments on the way, payers are thinking about tighter management. Formal treatment guidelines would help. Bio-markers could also sort out the 'right-drug, right-patient' conundrum.
23267282
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267281/can-we-afford-the-war-on-cancer
#6
JOURNAL ARTICLE
Can we afford the war on cancer?
Ed Silverman
Immunotherapy vaccines could extend survival in a handful of cancers. But personalizing treatment, payers argue, is not sustainable. Where should the line be drawn?
23267281
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267280/to-heal-the-body-get-into-the-patient-s-head-motivational-interviewing-to-improve-adherence
#7
JOURNAL ARTICLE
To Heal the Body, Get Into the Patient's Head: Motivational Interviewing: To improve adherence.
Jack McCain
For patients, poor adherence to biologics can increase risks of morbidity and mortality. For payers, it means money down the drain. Here's a tool that proponents say can help change patient behavior.
23267280
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267279/the-day-of-the-passive-purchaser-is-over-building-a-smarter-employer
#8
JOURNAL ARTICLE
The day of the passive purchaser is over: building a smarter employer.
Michael D Dalzell
In a system of healthcare financing that largely doesn't work for specialty drugs, the Midwest Business Group on Health is leading an ambitious initiative to educate and empower employers. The project's scope and potential outcomes are unprecedented.
23267279
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267278/biologics-clinical-trials-research-and-fda-actions
#9
JOURNAL ARTICLE
Biologics clinical trials, research, and FDA actions.
Michael D Dalzell
No abstract text is available yet for this article.
23267278
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267277/defined-contribution-and-alternative-care-meet-personalized-medicine
#10
JOURNAL ARTICLE
Defined contribution and alternative care meet personalized medicine.
F Randy Vogenberg
No abstract text is available yet for this article.
23267277
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23267276/choosing-health
#11
JOURNAL ARTICLE
Choosing health.
Katherine T Adams
No abstract text is available yet for this article.
23267276
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23091435/employers-target-rising-specialty-drug-costs
#12
JOURNAL ARTICLE
Employers target rising specialty drug costs.
Katherine T Adams
No abstract text is available yet for this article.
23091435
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23091434/ispot-d-trial-has-potential-to-personalize-antidepressant-treatment
#13
JOURNAL ARTICLE
iSPOT-D Trial Has Potential To Personalize Antidepressant Treatment.
Bob Carlson
No abstract text is available yet for this article.
23091434
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23091433/myriad-debate-over-gene-patents-continues
#14
JOURNAL ARTICLE
Myriad: debate over gene patents continues.
Joanna T Brougher
No abstract text is available yet for this article.
23091433
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23091432/drug-shortages-ease-but-have-we-gotten-to-the-root-of-the-problem
#15
JOURNAL ARTICLE
Drug shortages ease, but have we gotten to the root of the problem?
John Carroll
No abstract text is available yet for this article.
23091432
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23091431/will-comparative-effectiveness-research-finally-succeed
#16
JOURNAL ARTICLE
Will comparative effectiveness research finally succeed?
Erwin A Blackstone, Joseph P Fuhr, Danielle Ziernicki
Autonomy, innovation, and drug access may be at stake along with personalized medicine. Can all stakeholders be satisfied and should cost be a factor?
23091431
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23091430/putting-oncology-patients-at-risk
#17
JOURNAL ARTICLE
Putting oncology patients at risk.
Bob Carlson
Using genomic tests to personalize oncology treatment is a worthy endeavor. But when the rush to capitalize on biomedical research overcomes the rules of evidence, it's the patients who suffer.
23091430
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23091429/connecting-patients-with-specialty-products-part-2-the-future-of-specialty-drug-distribution
#18
JOURNAL ARTICLE
Connecting Patients With Specialty Products: Part 2: The future of specialty drug distribution.
Jack McCain
Previously, this series described distribution channels through which specialty drugs move to patients. This installment discusses changes and challenges that lie ahead, especially at the dispensing end.
23091429
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23091428/showdown-in-steel-city
#19
JOURNAL ARTICLE
Showdown in steel city.
Ed Silverman
Healthcare reform is encouraging the vertical integration of payers and providers. How far can this go in any one market before such efforts risk being deemed illegal? Pittsburgh provides a case study.
23091428
2012: Biotechnology Healthcare
https://read.qxmd.com/read/23091427/asco-the-science-was-grand-but-what-will-payers-think
#20
JOURNAL ARTICLE
ASCO: The Science Was Grand, But What Will Payers Think?
Michael D Dalzell
No abstract text is available yet for this article.
23091427
2012: Biotechnology Healthcare
next page »
journal
journal
40998
1
2
Make the most of Read.
Download the mobile app.
Fetch more papers »
Fetching more papers... Fetching...

All material on this website is protected by copyright, Copyright © 1994-2024 1994-{new Date().getFullYear()} by WebMD LLC.

By using this service, you agree to our terms of use and privacy policy.

Do Not Sell My Personal Information  Your Privacy Choices

Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

╳

We want to hear from doctors like you!

Take a second to answer a survey question.

╳